Glycobiology and Glycomics

Introduction to Glycobiology

Glycobiology is the study of the structure, biosynthesis, and biological functions of carbohydrates (glycans) and glycoconjugates—molecules in which sugars are attached to proteins (glycoproteins) or lipids (glycolipids). All cells are coated with a dense layer of glycans called the glycocalyx—a cell surface sugar code conveying identity, mediating cell-cell recognition, controlling protein folding and stability, modulating signalling receptors, protecting against proteolytic degradation, and mediating pathogen (viruses, bacteria) binding. Glycans are the most structurally complex class of biomolecules—monosaccharide building blocks can form branched structures with multiple linkage chemistries, creating an enormous combinatorial information density surpassing that of nucleic acids and proteins of equivalent molecular weight.

Despite glycans' abundance and biological importance, glycobiology lagged behind genomics and proteomics in systematic molecular characterisation because glycan synthesis is not template-driven (unlike DNA and protein) but is determined by the expression and localisation of glycosyltransferases and glycosidases—making prediction from genomic data alone insufficient. Advances in glycomics—the systematic characterisation of all glycan structures in a system—using mass spectrometry, glycan microarrays, and chemical biology tools have accelerated glycobiology research dramatically. Aberrant glycosylation is a near-universal feature of cancer, modulates viral immune evasion, and underlies over 160 known congenital disorders of glycosylation (CDGs).

Glycan Structural Diversity

N-linked Glycosylation

N-linked glycans are attached to asparagine in the consensus sequence Asn-X-Ser/Thr in the ER, transferred en bloc as a 14-residue precursor oligosaccharide (Glc3Man9GlcNAc2) by the oligosaccharyltransferase (OST) complex, then trimmed by glucosidases and ER mannosidases for calnexin/calreticulin quality control—retaining improperly folded glycoproteins until correctly folded. Further processing in Golgi produces three N-glycan classes: high-mannose (5-9 mannose residues), complex (multiple antennae with GlcNAc, galactose, sialic acid, fucose), and hybrid. N-glycans critically modulate protein folding, stability, secretion, receptor binding, half-life (sialylation shields asialoglycoprotein receptor-mediated hepatic clearance), and immune recognition. Biopharmaceutical glycosylation (IgGs, erythropoietin, TNF inhibitors) is a critical quality attribute controlled in bioreactor production.

O-linked Glycosylation and Mucins

O-linked glycans are attached to serine or threonine hydroxyl groups—initiated by polypeptide GalNAc transferases (GALNTs) adding Tn antigen (GalNAc-Ser/Thr) as the first residue, then extended by Core 1-8 synthases and branching enzymes producing diverse O-glycan cores. Mucins (MUC1-21) are highly O-glycosylated proteins constituting the mucus gel layer lining respiratory, GI, and reproductive tracts—their dense glycosylation providing hydration, lubrication, and pathogen trapping. Mucin O-glycosylation changes are among the earliest glycan alterations in cancer (Tn antigen exposure, truncated O-glycans)—providing cancer-specific glycan epitopes exploited in cancer detection (Ca-125, Ca 19-9) and immunotherapy (Tn antigen vaccines). O-GlcNAc modification of nuclear and cytoplasmic proteins is a dynamic signalling modification competing with phosphorylation and modulating transcription factors, metabolic enzymes, and stress responses.

Sialic Acid Biology

Siglecs and Immune Regulation

Sialic acids (Neu5Ac, Neu5Gc) are negatively charged 9-carbon sugars decorating the outermost glycan positions of mammalian cell surfaces, serving as molecular 'self' signals recognised by Siglec (sialic acid-binding immunoglobulin-type lectin) receptors on immune cells. Most Siglecs contain ITIM (immunoreceptor tyrosine inhibitory motif) cytoplasmic domains that dampen immune activation upon self-sialic acid recognition—preventing autoimmune attack while suppressing anti-tumour immunity. Tumours hypersialylate their surface (upregulating sialyltransferases ST6GAL1, ST8SIA2) engaging inhibitory Siglec-7 and Siglec-9 on NK cells and macrophages to evade immune killing. Anti-sialylation strategies (sialidase enzyme arming anti-tumour antibodies, sialyltransferases inhibitors) are in development to overcome tumour immune evasion through glycocalyx manipulation.

Glycans in Pathogen-Host Interactions

Pathogen binding and immune evasion frequently involve glycan-mediated interactions. Influenza hemagglutinin binds sialic acids for receptor engagement; receptor specificity (alpha-2,3 vs. alpha-2,6 sialic acid linkage) determines host range and tissue tropism. HIV gp120 is heavily glycosylated (>50% glycan by mass)—the glycan shield masking neutralisation epitopes from antibody recognition; broadly neutralising antibodies (VRC01, PGT121) developed against conserved glycan-protein epitopes demonstrate that the glycan shield paradoxically can guide vaccine design. Helicobacter pylori expresses Lewis blood group antigens mimicking host cell surface glycans, enabling immune evasion and persistent gastric colonisation. Streptococcus suis hyaluronic acid capsule inhibits complement deposition by mimicking host HA—convergent molecular mimicry through glycan biosynthesis.

Examples and Applications

Example 1: IgG Glycosylation and Antibody Function

IgG antibodies carry a conserved N-glycan at Asn-297 in the Fc region CH2 domain that fundamentally controls effector function. Afucosylated IgG (lacking core fucose from alpha-1,6-fucosyltransferase FUT8 activity) engages FcgammaRIIIa (CD16) on NK cells with 50-100x higher affinity, dramatically enhancing ADCC (antibody-dependent cellular cytotoxicity). Obinutuzumab (anti-CD20) is engineered to be afucosylated, providing superior ADCC versus fucosylated rituximab in CLL. High-sialylated IgG has anti-inflammatory properties—the mechanism of intravenous immunoglobulin (IVIG) anti-inflammatory effects—mediated through Siglec-7/DC-SIGN binding on DCs. Glycoengineering of therapeutic antibodies through FUT8 knockdown (mogamulizumab, margetuximab) to optimise Fc glycosylation for specified effector function has become standard in antibody drug development.

Example 2: Blood Group Antigens

ABO blood group antigens are glycan epitopes on red blood cells and many other cells. Type A antigen carries terminal GalNAc added by A transferase (encoded by ABO gene variant); type B carries terminal Gal from B transferase; type O lacks the terminal sugar from truncating ABO mutations produced a non-functional glycosyltransferase. Anti-A and anti-B antibodies (from gut microbiota cross-reactive exposure) in serologically non-matching recipients cause acute haemolytic transfusion reactions. The Lewis and Secretor blood group systems (FUT2, FUT3 glycosyltransferases) determine glycan expression in secretions and on RBCs—FUT2 non-secretors (~20% of population) lack H antigen in saliva and intestinal epithelium, showing resistance to norovirus (which binds H antigen) but increased H. pylori and C. difficile susceptibility due to altered gut mucosal glycans.

Example 3: Congenital Disorders of Glycosylation

CDGs are a growing group of >160 inherited metabolic diseases caused by mutations in genes encoding glycosyltransferases, glycosidases, or sugar nucleotide metabolic enzymes. CDG type 1a (PMM2-CDG, phosphomannomutase 2 deficiency)—the most common CDG—causes multisystem neurological disease including cerebellar ataxia, hypotonia, coagulopathy, and liver dysfunction due to global N-glycosylation deficiency from reduced GDP-mannose supply. Serum transferrin isoforms (hypoglycosylated transferrin bands on IEF or LC-MS) are diagnostic biomarkers. Dietary therapies supplementing monosaccharide building blocks (mannose for PMM2, fucose for SLC35C1-CDG causing leukocyte adhesion deficiency, galactose for PGM1-CDG) partially restore pathway flux. CDG diagnostics have expanded dramatically with whole exome sequencing identifying novel CDG genes in phenotypically complex patients.

Example 4: Cancer Glycan Biomarkers

Cancer-associated glycan alterations provide clinically useful biomarkers. CA-125 (MUC16 mucin glycoprotein)—elevated in ovarian cancer—is used for monitoring treatment response and recurrence; CA 19-9 (Lewis a glycan epitope on MUC5AC)—elevated in pancreatic and biliary cancer. Alpha-fetoprotein fucosylation variant (AFP-L3—core-fucosylated fraction)—elevated specifically in hepatocellular carcinoma versus benign liver disease. PSA glycoform differences between malignant and benign prostate disease improve PSA specificity. A comprehensive understanding of cancer glycome alterations (including sialylation, fucosylation, and aberrant O-glycosylation) is being translated into glycan-targeted therapeutic strategies including glycan-conjugated ADCs, glycan-specific T cell immunotherapy, and glycan-coating removal using systemic glycosidase enzyme therapy.

Example 5: Heparan Sulfate Proteoglycans

Heparan sulfate proteoglycans (HSPGs) present on cell surfaces and in ECM act as co-receptors for over 300 growth factors, morphogens, and signalling molecules including FGF, VEGF, Wnt, Hedgehog, BMP, and CXCL family chemokines. Heparan sulfate (HS) chains—long, variably sulfated polysaccharides synthesised on core proteins (syndecans, glypicans, agrin, perlecan)—constitute the binding scaffold for these factors, regulating their gradients, half-lives, and receptor presentation. Pathogen binding: herpes simplex virus gD binds HS for cell entry; SARS-CoV-2 Spike binds HS at abundant density on cell surfaces—potentially explaining the observation that heparin (structurally related to HS) competes with viral Spike RBD engagement. Heparin anticoagulant mechanism—HS binding antithrombin III increasing its rate of thrombin/Xa inhibition 1000-fold—is the most clinically relevant HSPG-protein interaction.

Example 6: Glycan Arrays for Lectin Profiling

Microarrays presenting hundreds of defined glycan structures printed on glass slides enable comprehensive profiling of glycan-binding proteins (lectins, antibodies, viruses, toxins). The Consortium for Functional Glycomics (CFG) and NCFG (National Center for Functional Glycomics) developed arrays with 600+ defined glycan structures from all major structural classes. Influenza virus binding to different sialic acid linkages (hemagglutinin HA binding profiles) on glycan arrays predicted host tropism and receptor specificity changes during pandemic emergence. Glycan array studies profiled coronavirus Spike lectin activities and discovered unexpected glycan interactions. Lectin histochemistry, flow cytometry using lectins, and glycan-targeted antibodies are applied to tissue pathology, blood group typing, and research characterising cell surface glycocalyx composition changes with differentiation and disease.

Example 7: Therapeutic Glycoproteins

Biopharmaceutical glycoproteins—erythropoietin (EPO), follicle-stimulating hormone (FSH), IgG antibodies, lysosomal enzyme replacement therapies—require precise glycosylation for function, half-life, and immunological properties. EPO contains 3 N-glycans and 1 O-glycan (40% of mass); terminal sialic acids prevent asialoglycoprotein receptor-mediated hepatic clearance—darbepoetin alfa (hyperglycosylated EPO variant with 5 N-glycan sites) has 3x longer half-life. Imiglucerase (recombinant glucocerebrosidase for Gaucher disease) requires terminal mannose-rich glycans for mannose receptor-mediated macrophage uptake and delivery to lysosomes—glycoengineered by selective trimming of complex N-glycans to expose mannose. CHO cell expression systems are the industry standard for glycoprotein production providing human-compatible glycosylation patterns; cell line engineering optimises glycosylation for desired pharmacological properties.

Example 8: Metabolic Glycan Labelling

Bioorthogonal chemistry—pioneered by Carolyn Bertozzi (2022 Nobel Prize in Chemistry, shared with Barry Sharpless and Morten Meldal)—enables labelling and modification of glycans in living cells and organisms with unprecedented specificity. Unnatural sugar analogues bearing bioorthogonal functional groups (azide-ManNAc for sialic acid labelling, azide-GalNAc for O-GlcNAc) are fed to cells and metabolically incorporated into glycans. Subsequent bioorthogonal reactions (Staudinger ligation with phosphines, strain-promoted azide-alkyne cycloaddition with cyclooctynes) attach fluorophores, drugs, or biotin to labelled glycans without perturbing living cell biology. In vivo metabolic labelling visualises: sialic acid dynamics on tumour cells for imaging, mucin glycosylation changes under inflammatory conditions, sialylated pathogen glycans for diagnostic imaging. Bertozzi's group also exploited this chemistry for in vivo glycocalyx editing—attaching PD-L1 antibody to tumour glycans using metabolic labelling and bioorthogonal attachment enabling glycocalyx-directed cancer immunotherapy.

Try it live

Everything above runs in your browser — open Glycobiology & Glycomics: Glycan Coat Simulator and change the parameters while it is running. Nothing is installed, nothing is uploaded, the whole model lives in one tab.